Related Experiment Videos

[Molecular factors determine primary and secondary therapy of breast carcinoma]

U Eppenberger1, W Kueng, S Eppenberger-Castori

  • 1Stiftung Tumorbank Basel, Universitäts-Frauenklinik.

Insights

Classical cancer treatments are insufficient, necessitating new molecular targets. Molecular classification of breast cancer using key proteins and biomarkers offers prognostic and predictive value for improved therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Context:

  • Classical chemo- and hormonal therapies show limitations in clinical oncology.
  • Emerging cellular and molecular structures offer novel therapeutic targets.
  • Key proteins in signal transduction cascades are often dysregulated in human tumors.

Purpose:

  • To explore molecular targets for new therapeutic approaches in cancer treatment.
  • To perform molecular classification of primary breast cancer.
  • To assess the prognostic and predictive value of specific molecular factors.

Summary:

  • Molecular classification of primary breast cancer involves assessing estrogen and progesterone receptors, ERbB-2, mutated p53, uPA, PAI-I, VEGF, DNA-Index, and S-Phase.
  • These molecular factors are crucial for understanding tumor biology and guiding treatment decisions.
  • Dysregulated proteins in signal transduction cascades represent key targets for novel oncological interventions.

Impact:

  • Identified molecular factors provide prognostic and predictive value for breast cancer patients.
  • This molecular approach challenges the sufficiency of traditional therapies.
  • Advances in understanding molecular targets pave the way for personalized cancer medicine.

Related Concept Videos